Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was … well, a weekend respite, and that you had a chance to indulge in a few distractions from the sobering events occurring outside your window. In any event, the time has come to resume something that resembles the usual routine — deadlines, phone calls, and meetings, on your laptop, that is. Meanwhile, here are a few items of interest to get you going. We hope your day is, nonetheless, productive and manageable. Meanwhile, be safe and be in touch.

States across the U.S. are taking steps to prevent hoarding of decades-old antimalarial drugs being used to combat Covid-19, an effort to preserve supplies for other patients who rely on the tablets to treat lupus and arthritis, The Wall Street Journal says. At least 20 states are implementing emergency restrictions or guidelines to ease pressure on supplies of hydroxychloroquine and chloroquine for the autoimmune disease patients. Some states are limiting prescription sizes or asking pharmacists to make sure a patient tested positive for the coronavirus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.